Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APL.
Status:
Recruiting
Trial end date:
2025-07-31
Target enrollment:
Participant gender:
Summary
ATRA is the standard of care for all patients with APL. The use of lower doses of ATRA has
been shown since the 1990s to achieve therapeutic efficacy with doses of 25mg/m2/day. ATO
demonstrated considerable effectiveness in this disease. More recently, an attenuated regimen
has been proven to be effective. In this study we intent to demonstrate the effectiveness of
combined therapy of low-dose ATRA plus attenuated dose ATO.